Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-10

  Emonds, Kimy M ^a   Swinnen, Johannes V ^b   Lerut, Evelyne ^a   Koole, Michel ^a   Mortelmans, Luc ^a   Mottaghy, Felix M ^a,c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KU Leuven and University Hospitals Leuven and Leuven Cancer Institute   (Belgium)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen deprivation; PET; Prostate cancer

Indexed keywords

ACETIC ACID C 11; ANDROGEN; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE WEIGHT; SEMINAL VESICLE; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84878784670     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-31     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. 18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostatespecific antigen relapse after radical prostatectomy. Clin Cancer Res 2005, 11:4761-4769.
3. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001, 57:108-111.
4. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M: Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999, 36:31-35.
5. Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR: Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003, 30:607-611.
6. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002, 98:19-22.
7. 11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003, 42:25-30.
8. Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K: Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004, 31:1064-1072.
9. Zhao C, Chen Z, Ye X, Zhang Y, Zhan H, Aburano T, Tian M, Zhang H: Imaging a pancreatic carcinoma xenograft model with 11C-acetate: a comparison study with 18F-FDG. Nucl Med Commun 2009, 30:971-977.
10. 11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007, 100:786-793.
11. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, Sadato N, Yonekura Y, Okada K: FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001, 22:963-969.
12. 11C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008, 35:1065-1073.
13. Fuccio C, Schiavina R, Castellucci P, Rubello D, Martorana G, Celli M, Malizia C, Profitos MB, Marzola MC, Pettinato V, Fanti S: Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011, 38:1985-1989.
14. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997, 3:402-408.
15. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999, 35:403-409.
16. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002, 62:6606-6614.
17. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 2003, 57:205-225.
18. Oyama N, Kim J, Jones LA, Mercer NM, Engelbach JA, Sharp TL, Welch MJ: MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol 2002, 29:783-790.
19. Boellaard R, van Lingen A, Lammertsma AA: Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med 2001, 42:808-817.
20. Kukuk D, Reischl G, Raguin O, Wiehr S, Judenhofer MS, Calaminus C, Honndorf VS, Quintanilla-Martinez L, Schönberger T, Duchamp O, Machulla HJ, Pichler BJ: Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models. J Nucl Med 2011, 52:1654-1663.
21. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen JV: Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 2001, 15:1817-1828.
22. Heemers H, Vanderhoydonc F, Roskams T, Shechter I, Heyns W, Verhoeven G, Swinnen JV: Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Mol Cell Endocrinol 2003, 205:21-31.
23. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM: Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011, 71:1486-1496.
24. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM: Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001, 61:3599-3603.
25. Emonds KM, Swinnen JV, van Weerden WM, Vanderhoydonc F, Nuyts J, Mortelmans L, Mottaghy FM: Do androgens control the uptake of 18FFDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? Eur J Nucl Med Mol Imaging 2011, 38:1842-1853.
26. Jadvar H, Gurbuz A, Li X, Shahinian A, Conti PS: Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging 2008, 7:147-152.
27. 11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37:301-309.
28. Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, Conti PS: Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging 2005, 4:91-97.